Literature DB >> 7954445

p53 deletion as a genetic marker in urothelial tumor by fluorescence in situ hybridization.

H Matsuyama1, Y Pan, E A Mahdy, P U Malmström, A Hedrum, M Uhlen, C Busch, T Hirano, G Auer, B Tribukait.   

Abstract

In order to investigate the significance of p53 deletion, 42 specimens of transitional cell carcinoma were analyzed by interphase cytogenetics with a fluorescence in situ hybridization technique and compared with clinicopathological and cytochemical parameters. In total, 27 (64%) and 16 (38%) specimens demonstrated p53 deletion and overexpression, respectively. The p53 deletion was significantly correlated with grade (P < 0.01), stage (P < 0.05), S-phase fraction (P < 0.05), and DNA ploidy (P < 0.01), while p53 overexpression correlated only with grade (P < 0.05). The close correlation of p53 deletion with clinicopathological parameters suggests p53 deletion to be of clinical importance to indicate the malignant potential of human urothelial tumors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7954445

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

Review 1.  New and promising strategies in the management of bladder cancer.

Authors:  Andrea B Apolo; Nicholas J Vogelzang; Dan Theodorescu
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

2.  Analysis of p53 gene deletions in colorectal cancers using fluorescence in situ hybridization.

Authors:  A Nanashima; Y Tagawa; T Yasutake; Y Taniguchi; T Sawai; T Nakagoe; H Ayabe
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

3.  Evaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers.

Authors:  Zhishuang Li; Jingjing Cui; Qiong Yu; Xiaojuan Wu; Aifeng Pan; Li Li
Journal:  Am J Transl Res       Date:  2016-01-15       Impact factor: 4.060

4.  Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.

Authors:  Qiong Yu; Yan Li; Kun Mu; Zhishuang Li; Qingyong Meng; Xiaojuan Wu; Yan Wang; Li Li
Journal:  Diagn Pathol       Date:  2014-03-25       Impact factor: 2.644

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.